DCM
ARQT icon

Dupont Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Dupont Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13,268
Closed -$389K – 1297
2020
Q3 		$389K Buy
+13,268
New +$354K 0.01% 876

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dupont Capital Management's ARQT Position: Q4 2020 in Review

Dupont Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2020, closing a stake of 13,268 shares — an estimated $389K sold.

Dupont Capital Management first reported a position in ARQT in Q3 2020 and held it in 1 quarter. The position peaked at $389K in Q3 2020. 78 funds tracked by Wall St. Rank hold ARQT as of Q4 2020.

  • Dupont Capital Management reported no remaining Arcutis Biotherapeutics position as of Q4 2020 after selling out during the quarter.
  • Dupont Capital Management sold 13,268 Arcutis Biotherapeutics shares in Q4 2020, an estimated $389K.
  • Dupont Capital Management first reported a position in Arcutis Biotherapeutics in Q3 2020 and held it in 1 quarter.
  • Dupont Capital Management's Arcutis Biotherapeutics position peaked at $389K in Q3 2020.
  • 78 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2020.

Based on Dupont Capital Management's 13F filing for Q4 2020, filed 28 Jan 2021.